Isolated peritoneal metastasis of prostate cancer is extremely rare. We present 68Ga-PSMA-11 PET/CT findings in a case of isolated parietal peritoneal metastasis from prostate adenocarcinoma 35 months after radical prostatectomy. The peritoneal metastases showed multifocal intense PSMA uptake, but subtle structural abnormalities on 68Ga-PSMA-11 PET/CT. The patient was subsequently treated with androgen deprivation therapy. The peritoneal metastases progressed 25 months after the initiation of androgen deprivation therapy and were removed surgically. Histologic and immunohistochemical evaluation revealed metastatic prostate adenocarcinoma with treatment-related neuroendocrine differentiation. This case demonstrates the usefulness of 68Ga-PSMA-11 PET/CT in identifying atypical metastasis from prostate adenocarcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/RLU.0000000000004805 | DOI Listing |
Sci Rep
January 2025
Nuclear Medicine Department, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
PET/CT targeting prostate-specific membrane antigen (PSMA) is commonly used in patients with prostate cancer. PSMA has been found in other solid tumours, including primary brain tumours. The aim of this study was to evaluate the usefulness of [Ga]Ga-PSMA-11 PET/CT for preoperative diagnosis and 2-year prognosis.
View Article and Find Full Text PDFSecond primary malignancies are being increasingly detected in the setting of thyroid cancer, because of adoption of the advanced imaging modalities including PET/CT. Herein, we present a patient of papillary thyroid carcinoma who initially underwent total thyroidectomy with bilateral neck dissection followed by 131I radioactive iodine therapy. A prostatic lesion was incidentally detected on 18F-FDG PET/CT scan, which was intensely 18F-FDG avid and also showed intense focal 68Ga-prostate-specific membrane antigen (PSMA) uptake on 68Ga-PSMA-11 PET/CT scan.
View Article and Find Full Text PDFJ Clin Invest
November 2024
Key Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
BACKGROUNDConsidering that trophoblast cell-surface antigen 2 (Trop2) is overexpressed in a wide range of human epithelial cancers, it presents an attractive target for diagnosis and treatment of multiple types of cancer. Herein, we have developed a Trop2-specific radiotracer, 68Ga-MY6349, and present a prospective, investigator-initiated trial to explore the clinical value of 68Ga-MY6349 PET/CT.METHODSIn this translational study, 90 patients with 15 types of cancer who underwent 68Ga-MY6349 PET/CT were enrolled prospectively.
View Article and Find Full Text PDFSichuan Da Xue Xue Bao Yi Xue Ban
September 2024
( 610041) Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective: In this study, we retrospectively analyzed the imaging characteristics of dual-tracer Ga-prostate specific membrane antigen (PSMA) and F-flurodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in metastatic prostate cancer (mPCa) patients. We analyzed the uptake modes of the dual tracers, explored clinical pathological parameters affecting the F-FDG uptake in the lesions, and evaluated their prognostic implications for prostate specific antigen progression-free survival (PSA-PFS).
Methods: A total of 41 mPCa patients who underwent dual-tracer PET/CT (Ga-PSMA and F-FDG) scans between September 2021 and January 2024 were retrospectively enrolled.
Clin Nucl Med
December 2024
LUX MED Oncology Hospital, Warsaw, Poland.
Purpose Of The Report: Endometrial cancer is the most common gynecological cancer. Prostate-specific membrane antigen (PSMA) is expressed in prostate cancer cells but can be found in other cancers, such as endometrial cancer, during angiogenesis.The aim of this prospective pilot study was to evaluate the feasibility of using 68Ga-PSMA-11 PET/CT in endometrial cancer patients before surgical treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!